Improving Global Outcomes (KDIGO) updated its clinical practice guideline for glomerular diseases in 2021, more than a decade after the first glomerular diseases guideline was published, reflecting slow progress in drug development. But since then, novel therapies for several glomerular diseases have been successfully tested and approved by regulatory agencies, none more so than IgA nephropathy (IgAN).
To keep pace with new therapies, the IgAN guideline was updated again in 2025. After this revision came to press, 3 additional IgAN treatments received accelerated approval by the US Food and Drug Administration.
Kidney International published a clinical update in Research Highlights on 25 Mar 2026. The item focuses on Complement inhibitors and B cell–modifying agents for IgA nephropathy—a Kidney Disease: Improving Global Outcomes (KDIGO) commentary. Open the detail page to review the full original feed content.